fully cashed up biotech

BOS had $4.95 million in the bank as at 31 Dec 2006 and only 103 million shares on issue - thats a cash backing of around 4.8 cents per share. Last trade at 15.5 cents. With a low burn rate, should not need to undertake a major capital raising for some time.

All we need now is for some postive news and progression towards commercialisation from one of their many colloborations with numerous major companies. Given the potential of their anti-bacterial compounds, surely its only a matter of time.

Expecting an announcement any time soon.